Phaseline

Targets › EBV

EBV: drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 3; Infectious disease, Oncology; next expected readout Jun 2027.

Open in Phaseline: the race on EBV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tobias FeuchtingerMultivirus (CMV, EBV, AdV)-specific T cells
Adoptive transfer of multivirus-specific T cells targeting CMV, EBV, and AdV
CMV, EBV, ADVPhase 3AdV InfectionMar 2028
Daihong LiuEBV-AST Cell Injection
Epstein-Barr virus antigen-specific cytotoxic T-lymphocyte product generated by ex vivo st
EBVPhase 1Epstein-Barr Virus-Associated Lymphoproliferative Disorders; EBV-DNA ViremiaJun 2027

Conditions

Epstein-Barr Virus-Associated Lymphoproliferative Disorders (1) EBV-DNA Viremia (1) AdV Infection (1)

Modalities

other (1)

Companies

Daihong Liu (1) Tobias Feuchtinger (1)

Related targets

CMV (1) ADV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.